Gyre Therapeutics, Inc. GYRE Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$9.86M— | —— | $5.94M+277% | $1.58M-57.8% | $3.73M+556% | ||
| $672K+2.4% | $656K+1.1% | $649K+1.2% | $641K+19.8% | $535K+16.1% | ||
| $2.58M-43.8% | $4.6M+301% | $1.15M+26.6% | $906K+78.7% | $507K-10.6% | ||
| -$16K-700% | -$2K-100% | -$1K— | —— | —— | ||
| -$8.57M-278% | $4.83M— | —— | —— | $722K-37.0% | ||
| $1.02M-16.0% | $1.21M— | $0-100% | $954K-38.1% | $1.54M+1,206% | ||
| $139K— | —— | $483K+1,047% | -$51K-464% | $14K+107% | ||
| $683K-71.3% | $2.38M+168% | -$3.51M— | —— | $4.44M— | ||
| $912K+79.2% | $509K+228% | -$398K— | —— | $5.54M+341% | ||
| —— | -$11.75K0.0% | -$11.75K0.0% | -$11.75K0.0% | -$11.75K-145% | ||
| $144K-44.8% | $261K— | —— | —— | -$2.27M— | ||
| —— | -$236K0.0% | -$236K— | —— | —— | ||
| $3.18M— | —— | $4.68M+124% | $2.09M+1,719% | -$129K+95.3% | ||
| $178K+23.6% | $144K-78.4% | $668K+161% | $256K+110% | $122K— | ||
| $10.07M+138% | $4.24M— | —— | —— | $11.19M— | ||
| $6K-45.5% | $11K— | $0-100% | $18K+1,700% | $1K-99.3% | ||
| $5K— | $0-100% | $15K-34.8% | $23K-96.7% | $699K-13.7% | ||
| —— | —— | —— | —— | —— | ||
| -$3.06M— | —— | -$1.25M+59.0% | -$3.04M-255% | $1.97M+198% | ||
| $21K-93.4% | $318K+536% | $50K-96.6% | $1.48M+191% | $509K— | ||
| —— | —— | —— | $1.68M+1,289% | $121K-67.0% | ||
| $21K-93.4% | $318K-12.9% | $365K-98.4% | $22.35M+1,563% | $1.34M+39.4% | ||
| $285K+124% | $127K+8.5% | $117K+139% | $49K-2.0% | $50K+120% | ||
| $431K— | —— | $3.91M-81.8% | $21.45M+564% | $3.23M+180% | ||
| $1.21M+7.6% | $1.13M+64.2% | $687K+53.7% | $447K-86.7% | $3.36M+341% | ||
| —— | -$7K0.0% | -$7K0.0% | -$7K0.0% | -$7K-103% | ||
| -$647K— | —— | —— | —— | -$483K— | ||
| $195K+674% | -$34K+37.0% | -$54K+66.9% | -$163K-187% | $188K+165% | ||
| —— | —— | —— | —— | $39K-36.1% | ||
| —— | —— | —— | —— | $39K-36.1% | ||
| -$738K-748% | -$87K+83.6% | -$531K-77.0% | -$300K-57.1% | -$191K+67.7% | ||
| -$21K-5.0% | -$20K-5.3% | -$19K0.0% | -$19K0.0% | -$19K-11.8% | ||
| $683K-71.3% | $2.38M+168% | -$3.51M— | —— | $4.44M— | ||
| —— | -$2500.0% | -$2500.0% | -$2500.0% | -$250+75.0% | ||
| $144K-44.8% | $261K— | —— | —— | -$2.27M— | ||
| $912K+79.2% | $509K+228% | -$398K— | —— | $5.54M+341% | ||
| —— | —— | —— | —— | $25K— | ||
| $217K+26.9% | $171K-17.0% | $206K+1.5% | $203K+3.0% | $197K-0.5% | ||
| —— | —— | —— | —— | —— | ||
| $5K— | $0-100% | $15K-34.8% | $23K-96.7% | $699K-13.7% | ||
| $12.95M+358% | $2.83M— | $0-100% | $2.78M-66.9% | $8.4M+502% | ||
| $6K-45.5% | $11K— | $0-100% | $18K+1,700% | $1K-99.3% | ||
| $285K+124% | $127K+8.5% | $117K+139% | $49K-2.0% | $50K+120% | ||
| -$89K+66.2% | -$263K-1,243% | $23K+111% | -$212K+90.6% | -$2.26M-1,062% | ||
| -$1.9M-139% | $4.85M+2,624% | $178K+111% | -$1.64M+27.1% | -$2.24M-152% | ||
| $1.21M+7.6% | $1.13M+64.2% | $687K+53.7% | $447K-86.7% | $3.36M+341% | ||
| $3M+152% | -$5.77M-244% | $4.01M+119% | $1.83M+830% | -$251K+90.7% | ||
| $3M+152% | -$5.77M-244% | $4.01M+119% | $1.83M+830% | -$251K+90.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Gyre Therapeutics, Inc. generate?
- Gyre Therapeutics, Inc. (GYRE) generated $9.8M in operating cash flow over the trailing twelve months.
- What is Gyre Therapeutics, Inc.'s free cash flow?
- After $1.2M of capital expenditures, Gyre Therapeutics, Inc.'s free cash flow was $3.1M over the trailing twelve months, up 142.4% year over year.
- Where does Gyre Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Gyre Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
